| Serial Number | 87763013 |
| Word Mark | NAVIO |
| Filing Date | Friday, January 19, 2018 |
| Status | 606 - ABANDONED - NO STATEMENT OF USE FILED |
| Status Date | Monday, September 11, 2023 |
| Registration Number | 0000000 |
| Registration Date | NOT AVAILABLE |
| Mark Drawing | 4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
| Published for Opposition Date | Tuesday, October 20, 2020 |
| Goods and Services | Physician support services in the nature of providing legal consultation in the dispensing of prescription drugs for persons with particular cancers; providing survivorship information in the field of oncology, namely, legal advice regarding survivorship; provide individualized expert legal advice and diagnosis |
| Translation of Words in Mark | The English translation of "NAVIO" in the mark is "SHIP". |
| Goods and Services | Medical services in the field of oncology, nephrology; dispensing of pharmaceuticals; medical and pharmaceutical consultation; pharmaceutical advice; pharmaceutical compounding services; providing information relating to diagnostic, prophylactic and therapeutic properties of pharmaceuticals; medical services, namely, providing personalized drug therapy management programs to cancer patients based on the patient's genetic testing results; genetic testing for medical purposes; genetic testing for cancer diagnosis, treatment and prevention purposes; providing genetic sequencing and consulting services via website designed to provide cancer patients and oncologists with custom tailored information about the range of possible treatments and drug therapies for a particular cancer; providing information to patients and physicians via a website to recommend cancer treatment and drug therapies based on the patient's genetic testing results; providing personalized drug therapy services for cancer patients; drug utilization review dispensing services via a website, namely, identifying cancer drug therapies based on a patient's genetic testing results prior to dispensing medications; developing and managing comprehensive treatment programs involving drug therapy, namely, providing comprehensive medical treatment programs involving drug therapy for the treatment of cancer; physician support services in the nature of providing medical consultation in the dispensing of prescription drugs for persons with particular cancers; providing medical evaluations of patients to determine acceptability for participation in clinical trials; providing healthcare medical counseling, screening, diagnosis, prognosis, treatment, relapse, palliative, integrative medicine, survivorship information, namely, providing comprehensive medical treatment programs involving drug therapy, and other related medical information in the field of oncology; Health care services, namely, providing a database in the field of oncology information and featuring inputting and collection of data and information all for treatment and diagnosis purposes; healthcare consultation in the field of cancer treatment research, namely, advising patients on cancer treatment research studies in which they might participate for purposes of treating their conditions; providing an online searchable database in the fields of oncology, bioinformatics, clinical information technology, genomic data and genomic sequence analysis for personalized diagnosis, treatment and prevention of cancer; molecular profiling for providing comprehensive medical treatment programs involving drug therapy for providing medical treatment; providing RNA expression analysis for medical treatment and diagnosis; providing personalized immunotherapy; Medical services, namely, providing cancer diagnosis; providing standard diagnostics and comprehensive diagnostics, namely, providing standard and comprehensive medical testing for diagnostic purposes; medical services, namely, providing personalized drug screening; providing real-time therapeutic response monitoring for medical treatment and diagnostic purposes; provide individualized expert medical advice and diagnosis in the field of oncology; provide machine learning based medical treatment for cancer patients; providing personalized molecular tumor for each patient, namely, providing medical treatment in the nature of providing personalized molecular tumor for each patient for the treatment of cancer; molecular profiling for oncology treatment purposes; providing RNA expression analysis for oncology treatment purposes; providing standard diagnostics and comprehensive diagnostics, namely, oncology patient diagnostic services for medical treatment purposes; providing personalized drug screening for oncology patients for medical purposes; providing real-time therapeutic response monitoring for oncology patients for medical purposes; providing personalized drug screening for medical treatment and diagnostic purposes; provide machine learning based treatment in the nature of medical treatment and diagnostic purposes for cancer patients |
| Goods and Services | Medical, clinical and scientific research in the field of oncology, namely, research relating to genetic diagnostic assays and pharmaceuticals for personalized diagnosis, treatment and prevention of cancer; scientific and technological services, namely, research services for medical purposes in the field of genetic diagnostic assays and pharmaceuticals research for personalized diagnosis, treatment and prevention of cancer; providing medical and scientific research information and scientific consulting in the field of genetic diagnostic assays and pharmaceuticals for diagnosis, treatment and prevention of cancer; conducting early evaluations in the field of new genetic diagnostics assays and pharmaceuticals; development, evaluation and medical and scientific research of genetic diagnostic assays for personalized diagnosis, treatment and prevention of cancer; laboratory research services relating to genetic diagnostic assays for personalized diagnosis, treatment and prevention of cancer; providing medical and scientific research information in the field of genetic diagnostic assays, pharmaceuticals, clinical trials and genetics; technical consulting related to scientific and medical studies in the field of genetic diagnostic assay and pharmaceuticals for personalized diagnosis, treatment and prevention of cancer; basic and clinical research in the field of oncology, namely, researching genetic diagnostic assays and pharmaceuticals for personalized diagnosis, treatment and prevention of cancer; providing medical and scientific research information in the field of genetic diagnostic assays, pharmaceuticals and clinical trials for personalized diagnosis, treatment and prevention of cancer; custom design and development of chemical reagents and multiplex sequencing assays for personalized diagnosis, treatment and prevention of cancer; providing an on-line computer database featuring medical and scientific research information in the field of oncology that allows for input and collection of scientific and research data and information relating to genetic diagnostic assays and pharmaceuticals for diagnosis, treatment and prevention of cancer; data collection for research purposes, namely, data mining and pattern recognition, designing clinical studies, and generating genomic data from patient samples for personalized diagnosis, treatment and prevention of cancer; data collection for research purposes, namely, the collection and systematic sorting of clinical and patient data comprising patient specific clinical data and scientific clinical studies relating to genetic diagnostic assays and pharmaceuticals for personalized diagnosis, treatment and prevention of cancer; data collection for research purposes, namely, the collection of mathematical and statistical data, clinical data, patient data and data of clinical studies relating to clinical response to cancer treatments for personalized diagnosis, treatment and prevention of cancer; compiling data for research purposes in the field of medical science, namely, compiling patient specific molecular and genomic data, patient specific clinical data and scientific clinical studies for personalized diagnosis, treatment and prevention of cancer; providing a website featuring technology with a web-based interface where medical professionals can view genetic test results and interpretations of the results by scientists and medical professionals in the field of genomics, and select the appropriate treatment and order the necessary pharmaceutical products; providing personalized molecular tumor for each patient, namely, providing medical research information regarding personalized molecular tumor treatments; providing medical research and scientific research information in the field of oncology via the Internet; development of a personalized ctDNA (circulating tumor DNA) assay; molecular profiling for scientific research purposes; providing RNA expression analysis for scientific research purposes; providing standard diagnostics and comprehensive diagnostics, namely, oncology patient diagnostic services for scientific research purposes; providing personalized drug screening for oncology patients for medical research purposes; providing real-time therapeutic response monitoring for oncology patients for medical research purposes; providing crowdsourcing platform in the nature of providing online non-downloadable software for obtaining information and input into a take or project by enlisting the services of a large number of people; molecular profiling for providing comprehensive medical treatment programs involving drug therapy for providing medical research; providing a database in the field of oncology and featuring inputting and collection of data and information all for treatment and diagnosis purposes, namely, providing a computer database in the field of oncology for treatment and diagnosis purposes featuring technology that allows users to input and collect data and information |
| International Class | 042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Wednesday, January 31, 2018 |
| Primary Code | 042 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 044 - Medical services; veterinary services; hygienic and beauty care for human beings or animals; agriculture, horticulture and forestry services. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Wednesday, January 31, 2018 |
| Primary Code | 044 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 045 - Legal services; security services for the protection of property and individuals; personal and social services rendered by others to meet the needs of individuals. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Thursday, November 8, 2018 |
| Primary Code | 045 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| Party Name | Navio Theragnostics, Inc. |
| Party Type | 20 - Owner at Publication |
| Legal Entity Type | 03 - Corporation |
| Address | San Mateo, CA 94401 |
| Party Name | Navio Theragnostics, Inc. |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 03 - Corporation |
| Address | San Mateo, CA 94401 |
| Event Date | Event Description |
| Monday, September 11, 2023 | ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED |
| Monday, September 11, 2023 | ABANDONMENT - NO USE STATEMENT FILED |
| Thursday, February 2, 2023 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Tuesday, January 31, 2023 | SOU EXTENSION 4 GRANTED |
| Tuesday, January 31, 2023 | SOU EXTENSION 4 FILED |
| Tuesday, January 31, 2023 | SOU TEAS EXTENSION RECEIVED |
| Wednesday, August 10, 2022 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Monday, August 8, 2022 | SOU EXTENSION 3 GRANTED |
| Monday, August 8, 2022 | SOU EXTENSION 3 FILED |
| Monday, August 8, 2022 | SOU TEAS EXTENSION RECEIVED |
| Friday, February 11, 2022 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Wednesday, February 9, 2022 | SOU EXTENSION 2 GRANTED |
| Wednesday, February 9, 2022 | SOU EXTENSION 2 FILED |
| Wednesday, February 9, 2022 | SOU TEAS EXTENSION RECEIVED |
| Saturday, August 7, 2021 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Thursday, August 5, 2021 | SOU EXTENSION 1 GRANTED |
| Thursday, August 5, 2021 | SOU EXTENSION 1 FILED |
| Thursday, August 5, 2021 | SOU TEAS EXTENSION RECEIVED |
| Tuesday, February 9, 2021 | NOA E-MAILED - SOU REQUIRED FROM APPLICANT |
| Wednesday, December 30, 2020 | EXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED |
| Friday, November 13, 2020 | EXTENSION OF TIME TO OPPOSE RECEIVED |
| Tuesday, October 20, 2020 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Tuesday, October 20, 2020 | PUBLISHED FOR OPPOSITION |
| Wednesday, September 30, 2020 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Monday, September 14, 2020 | EXPARTE APPEAL TERMINATED |
| Monday, September 14, 2020 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Thursday, September 3, 2020 | EXAMINER'S AMENDMENT ENTERED |
| Thursday, September 3, 2020 | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED |
| Thursday, September 3, 2020 | EXAMINERS AMENDMENT E-MAILED |
| Thursday, September 3, 2020 | EXAMINERS AMENDMENT -WRITTEN |
| Saturday, August 15, 2020 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Saturday, August 15, 2020 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Wednesday, August 12, 2020 | TEAS REQUEST FOR RECONSIDERATION RECEIVED |
| Wednesday, August 12, 2020 | EX PARTE APPEAL-INSTITUTED |
| Wednesday, August 12, 2020 | JURISDICTION RESTORED TO EXAMINING ATTORNEY |
| Wednesday, August 12, 2020 | EXPARTE APPEAL RECEIVED AT TTAB |
| Tuesday, February 18, 2020 | NOTIFICATION OF FINAL REFUSAL EMAILED |
| Tuesday, February 18, 2020 | FINAL REFUSAL E-MAILED |
| Tuesday, February 18, 2020 | FINAL REFUSAL WRITTEN |
| Friday, January 24, 2020 | SUSPENSION CHECKED - TO ATTORNEY FOR ACTION |
| Wednesday, June 19, 2019 | REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED |
| Friday, June 14, 2019 | ASSIGNED TO LIE |
| Thursday, November 29, 2018 | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED |
| Thursday, November 29, 2018 | LETTER OF SUSPENSION E-MAILED |
| Thursday, November 29, 2018 | SUSPENSION LETTER WRITTEN |
| Thursday, November 8, 2018 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Wednesday, November 7, 2018 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Wednesday, November 7, 2018 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Tuesday, May 8, 2018 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Tuesday, May 8, 2018 | NON-FINAL ACTION E-MAILED |
| Tuesday, May 8, 2018 | NON-FINAL ACTION WRITTEN |
| Monday, April 30, 2018 | ASSIGNED TO EXAMINER |
| Wednesday, January 31, 2018 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Tuesday, January 23, 2018 | NEW APPLICATION ENTERED |